Acute Myeloid Leukemia Cell Models

MA9.3ITD (MLL-AF9 fusion gene plus FLT3-ITD mutation; MLL, also known as KMT2A) and MA9.3RAS (MLL-AF9 fusion gene plus NRAS^G12D mutation) were established by Dr. James Mulloy and cultured in IMDM supplemented with 20% FBS.^{21 (link)} MONOMAC 6, MV4-11, MOLM13, Kasumi-1, THP-1, SKNO-1 and ML-2 are obtained and maintained as previously described.^{22 (link)} Homoharringtonine purchased from Sigma-Aldrich was used in this study.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Li C., Dong L., Su R., Bi Y., Qing Y., Deng X., Zhou Y., Hu C., Yu M., Huang H., Jiang X., Li X., He X., Zou D., Shen C., Han L., Sun M., Skibbe J., Ferchen K., Qin X., Weng H., Huang H., Song C., Chen J, & Jin J. (2020). Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica, 105(1), 148-160.

Publication 2019

Homoharringtonine

Flt3 Gene mutation Homoharringtonine Kmt2a Monomac

Corresponding Organization :

Other organizations : First Affiliated Hospital Zhejiang University, City of Hope, University of Cincinnati, Ludwig Cancer Research, China Medical University, Northwestern University, Zhejiang University, Chongqing Cancer Hospital, Chongqing University, Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical Center

Top 5 similar protocols

Variable analysis

independent variables

MA9.3ITD (MLL-AF9 fusion gene plus FLT3-ITD mutation)
MA9.3RAS (MLL-AF9 fusion gene plus NRASG12D mutation)

dependent variables

Cell culture growth and maintenance

control variables

IMDM supplemented with 20% FBS culture medium
MONOMAC 6, MV4-11, MOLM13, Kasumi-1, THP-1, SKNO-1 and ML-2 cell lines

positive controls

Not specified

negative controls

Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!